

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

NCI-H322

RRID:CVCL_1556

Type: Cell Line

Proper Citation

RRID:CVCL_1556

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1556

Proper Citation: RRID:CVCL_1556

Description: Cell line NCI-H322 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Minimally invasive lung adenocarcinoma

Defining Citation: [PMID:1311061](#), [PMID:1565469](#), [PMID:2386953](#), [PMID:2388294](#), [PMID:3335022](#), [PMID:7972006](#), [PMID:8806092](#), [PMID:10536175](#), [PMID:11005564](#), [PMID:11030152](#), [PMID:11416159](#), [PMID:19472407](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:20679594](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#)

Comments: Caution: We are not certain that NCI-H322 and NCI-H322M are identical., Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H322

Synonyms: H322, H-322, H322T, NCI-H322T, NCIH322T, NCI-322, NCIH322

Cross References: BTO:BTO_0003007, CLO:CLO_0008083, EFO:EFO_0006691, CLDB:cl3655, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ATCC:CRL-5806, BioGRID_ORCS_Cell_line:525, BioSample:SAMN03471699, BioSample:SAMN03471740, BioSample:SAMN03473287, BioSample:SAMN10987678, cancercellines:CVCL_1556, ChEMBL-

Cells:CHEMBL3307405, ChEMBL-Targets:CHEMBL614573, CLS:305839, Cosmic:687822, Cosmic:801589, Cosmic:844830, Cosmic:876143, Cosmic:903571, Cosmic:917976, Cosmic:929972, Cosmic:932922, Cosmic:934547, Cosmic:980962, Cosmic:1028935, Cosmic:1032434, Cosmic:1146913, Cosmic:1152500, Cosmic:1239903, Cosmic:1802317, Cosmic:1870261, Cosmic:1891884, Cosmic:2042867, Cosmic:2125250, Cosmic:2648438, Cosmic:2668312, DepMap:ACH-000837, ECACC:95111734, EGA:EGAS00001000610, GEO:GSM171876, GEO:GSM171877, GEO:GSM206490, GEO:GSM253358, GEO:GSM274757, GEO:GSM274758, GEO:GSM434333, GEO:GSM784245, GEO:GSM794282, GEO:GSM817070, GEO:GSM827434, GEO:GSM887426, GEO:GSM888506, GEO:GSM1374741, IARC_TP53:516, IGRhCellID:NCIH322, KCLB:90322, LiGeA:CCLE_305, LINCS_LDP:LCL-1798, PharmacDB:NCIH322_1105_2019, Progenetix:CVCL_1556, PubChem_Cell_line:CVCL_1556, Wikidata:Q54908033

ID: CVCL_1556

Record Creation Time: 20220427T220839+0000

Record Last Update: 20260829T234733+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H322.

Warning: Discontinued: ATCC; CRL-5806

Caution: We are not certain that NCI-H322 and NCI-H322M are identical., Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). **Warning:** Discontinued: KCLB; 90322

Caution: We are not certain that NCI-H322 and NCI-H322M are identical., Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Takano K, et al. (2026) DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. Molecular cancer therapeutics, 25(1), 7.

Li HS, et al. (2025) RANKL/PD-1 dual blockade demonstrates survival benefit for patients with advanced lung adenocarcinoma harboring KRAS mutations. Cell reports. Medicine, 6(7), 102235.

Xiao C, et al. (2025) RAD21-mediated epigenetic regulation promotes lung adenocarcinoma progression and sensitizes cancer cells to ERK-targeted therapy. *Cancer letters*, 634, 218062.

Mizusaki S, et al. (2025) NECTIN4 regulates the cell surface expression of CD155 in non-small cell lung cancer cells and induces tumor resistance to PD-1 inhibitors. *Cancer immunology, immunotherapy : CII*, 74(7), 211.

Branco H, et al. (2025) Preclinical studies on the antitumor and non-toxic effect of combining pirfenidone with vinorelbine and carboplatin in non-small cell lung cancer. *International journal of cancer*, 156(9), 1756.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. *Cancer cell*, 43(8), 1530.

Huang HY, et al. (2024) Incense-burning smoke ingredient Auramine enhances lincRNA-p21 expression for chemosensitization in p53-mutated non-small cell lung cancer. *Journal of hazardous materials*, 477, 135105.

Sun H, et al. (2024) TERC promotes non-small cell lung cancer progression by facilitating the nuclear localization of TERT. *iScience*, 27(6), 109869.

Kotagiri S, et al. (2024) Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer. *Cell chemical biology*, 31(12), 2069.

Aboukassim T, et al. (2023) A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants. *Cell reports*, 42(9), 113104.

DeBlasi JM, et al. (2023) Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression. *Cancer research*, 83(12), 1953.

Kennedy PR, et al. (2023) A tri-specific killer engager against mesothelin targets NK cells towards lung cancer. *Frontiers in immunology*, 14, 1060905.

Kwon M, et al. (2022) Smoking-associated Downregulation of FILIP1L Enhances Lung Adenocarcinoma Progression Through Mucin Production, Inflammation, and Fibrosis. *Cancer research communications*, 2(10), 1197.

Limagne E, et al. (2022) MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells. *Cancer cell*, 40(2), 136.

Cooke M, et al. (2021) FARP1, ARHGEF39, and TIAM2 are essential receptor tyrosine kinase effectors for Rac1-dependent cell motility in human lung adenocarcinoma. *Cell reports*, 37(5), 109905.

Orre LM, et al. (2019) SubCellBarCode: Proteome-wide Mapping of Protein Localization and Relocalization. *Molecular cell*, 73(1), 166.

Lee HH, et al. (2019) Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. *Cancer cell*, 36(2), 168.

Kang YP, et al. (2019) Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer. *eLife*, 8.

Liang CJ, et al. (2019) SFRPs Are Biphasic Modulators of Wnt-Signaling-Elicited Cancer Stem Cell Properties beyond Extracellular Control. *Cell reports*, 28(6), 1511.

Huang R, et al. (2018) Identification of potential diagnostic and prognostic biomarkers in non-small cell lung cancer based on microarray data. *Oncology letters*, 15(5), 6436.